Skip to main content
Anas Younes, MD, Oncology, New York, NY

AnasYounesMD

Oncology New York, NY

Senior VP, and Global Head of Hematology R&D at AstraZeneca

Dr. Younes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Younes' full profile

Already have an account?

Summary

  • Anas Younes

Education & Training

  • Memorial Sloan-Kettering Cancer Center
    Memorial Sloan-Kettering Cancer CenterFellow, medical oncology, 1989 - 1992
  • SUNY Health Science Center at Brooklyn
    SUNY Health Science Center at BrooklynResidency, Internal Medicine, 1986 - 1989
  • University of Toledo
    University of ToledoResidency, Pathology-Anatomic and Clinical, 1985 - 1986
  • Damascus University Faculty of Medicine
    Damascus University Faculty of MedicineClass of 1983

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1988 - 2027
  • NJ State Medical License
    NJ State Medical License 2019 - 2021
  • TX State Medical License
    TX State Medical License 1992 - 2013
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • top doctor castle connoly, 2017
  • Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Long‐Term Overall‐ and Progression‐Free Survival After Pentostatin, Cyclophosphamide and Rituximab Therapy for Indolent Non‐Hodgkin Lymphoma  
    Peter McLaughlin, M Alma Rodriguez, Sattva S Neelapu, Anas Younes, Lei Feng, Michelle A Fanale, Felipe Samaniego, Barbara Pro, Luis Fayad, Fredrick Hagemeister, Jorge ..., British Journal of Haematology
  • NOXA Genetic Amplification or Pharmacologic Induction Primes Lymphoma Cells to BCL2 Inhibitor-Induced Cell Death  
    Anas Younes, MD, Proceedings of the National Academy of Sciences
  • Rituximab with ABVD vs ABVD for Advanced Stage High-Risk Classical Hodgkin Lymphoma: A Randomized Phase II Study  
    Francesco Turturro, Luis E Fayad, Anas Younes, Michelle Fanale, Yasuhiro Oki, Hun Ju Lee, Nancy L Bartlett, Haematologica

Abstracts/Posters

  • Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
    Anas Younes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial
    Anas Younes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
    Anas Younes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax i... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analys... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Taking on New Challenges: 8 Questions with Gilles Salles
    Taking on New Challenges: 8 Questions with Gilles SallesDecember 23rd, 2020
  • Physicians’ Education Resource® Presents the 3rd Annual Live Medical Crossfire®: Hematologic Malignancies
    Physicians’ Education Resource® Presents the 3rd Annual Live Medical Crossfire®: Hematologic MalignanciesJune 20th, 2019
  • Annual European Congress on Hematology™: Focus on Lymphoid Malignancies
    Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesOctober 4th, 2018
  • Join now to see all

Committees

  • Co-author, Committee on Appropriateness Criteria, Expert Panel on Radiation Oncology - Lymphoma, American College of Radiology 2015 - Present